creatine and Akinetic-Rigid Variant of Huntington Disease studies

Research Excerpts

Excerpt	Relevance	Reference
"To investigate whether creatine administration could slow progressive functional decline in adults with early symptoms of Huntington disease."	9.24	The CREST-E study of creatine for Huntington disease: A randomized controlled trial. ( Bredlau, AL; Hersch, SM; Meyers, CM; Nahin, R; Oakes, D; Rosas, HD; Schifitto, G, 2017)
"In a randomized, double-blind, placebo-controlled study in 64 subjects with Huntington disease (HD), 8 g/day of creatine administered for 16 weeks was well tolerated and safe."	9.12	Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. ( Beal, MF; Bogdanov, M; Como, P; Cox, M; Ebbel, E; Feigin, A; Ferrante, R; Gevorkian, S; Hersch, SM; Hevelone, N; Jenkins, B; Kaneko, Y; Lin, M; Marder, K; Matson, W; Moskowitz, C; Rosas, HD; Schoenfeld, D; Ulug, AM; Yu, H; Zaleta, A; Zhang, H; Zhang, L; Zimmerman, C, 2006)
"Treatment with creatine supplements ameliorated the hearing impairment of HD mice, suggesting that the impaired PCr-CK system in the cochlea of HD mice may contribute to their hearing impairment."	5.37	Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. ( Chen, CM; Chen, HM; Cheng, ML; Chern, Y; Lin, YJ; Lin, YS; Poon, PW; Soong, BW; Wang, CH; Wu, DR; Wu, YR; Yeh, WY, 2011)
"To investigate whether creatine administration could slow progressive functional decline in adults with early symptoms of Huntington disease."	5.24	The CREST-E study of creatine for Huntington disease: A randomized controlled trial. ( Bredlau, AL; Hersch, SM; Meyers, CM; Nahin, R; Oakes, D; Rosas, HD; Schifitto, G, 2017)
"In a randomized, double-blind, placebo-controlled study in 64 subjects with Huntington disease (HD), 8 g/day of creatine administered for 16 weeks was well tolerated and safe."	5.12	Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. ( Beal, MF; Bogdanov, M; Como, P; Cox, M; Ebbel, E; Feigin, A; Ferrante, R; Gevorkian, S; Hersch, SM; Hevelone, N; Jenkins, B; Kaneko, Y; Lin, M; Marder, K; Matson, W; Moskowitz, C; Rosas, HD; Schoenfeld, D; Ulug, AM; Yu, H; Zaleta, A; Zhang, H; Zhang, L; Zimmerman, C, 2006)
"Huntington's disease is a rare hereditary degenerative disease with a wide variety of symptoms that encompass movement, cognition, and behavior."	2.52	Therapeutic advances in Huntington's Disease. ( Fraint, A; Shannon, KM, 2015)
"In addition to HD-related hearing impairment, inferior CKB expression and/or an impaired PCr-CK system may also play an important role in other hearing impairments caused by elevated levels of ROS."	2.47	Besides Huntington's disease, does brain-type creatine kinase play a role in other forms of hearing impairment resulting from a common pathological cause? ( Chern, Y; Lin, YS; Wang, CH, 2011)
"A wide variety of models of Huntington's disease have been developed including yeast, Caenorhabditis elegans, Drosophila melanogaster and mouse."	2.42	Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? ( Bates, GP; Hockly, E, 2003)
"Treatment with creatine supplements ameliorated the hearing impairment of HD mice, suggesting that the impaired PCr-CK system in the cochlea of HD mice may contribute to their hearing impairment."	1.37	Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. ( Chen, CM; Chen, HM; Cheng, ML; Chern, Y; Lin, YJ; Lin, YS; Poon, PW; Soong, BW; Wang, CH; Wu, DR; Wu, YR; Yeh, WY, 2011)
"Creatine treatment started at 6, 8, and 10 weeks of age, analogous to early, middle, and late stages of human HD, significantly extended survival at both the 6- and 8-week starting points."	1.32	Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. ( Beal, MF; Dedeoglu, A; Ferrante, KL; Ferrante, RJ; Hersch, SM; Kubilus, JK; Yang, L, 2003)
" Using this assay, we show that Congo red and chrysamine G can modulate aggregate formation, but show complex dose-response curves."	1.31	Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. ( Bates, GP; Hockly, E; Klunk, WE; Li, XJ; Mahal, A; Murray, KD; Portier, R; Smith, DL; Wanker, E; Woodman, B, 2001)
"The gene defect in Huntington's disease (HD) may result in an impairment of energy metabolism."	1.30	Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. ( Beal, MF; Ferrante, RJ; Jenkins, BG; Kaddurah-Daouk, R; Matthews, RT; Rosen, BR; Yang, L, 1998)

Research

Studies (35)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Change in Behavioral Frequency Score From Baseline to Month 60

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (8.57)	18.2507
2000's	20 (57.14)	29.6817
2010's	11 (31.43)	24.3611
2020's	1 (2.86)	2.80

Authors	Studies
McGarry, A	1
Gaughan, J	1
Hackmyer, C	1
Lovett, J	1
Khadeer, M	1
Shaikh, H	1
Pradhan, B	1
Ferraro, TN	1
Wainer, IW	1
Moaddel, R	1
Hersch, SM	6
Schifitto, G	1
Oakes, D	1
Bredlau, AL	1
Meyers, CM	1
Nahin, R	1
Rosas, HD	4
Casseb, RF	1
D'Abreu, A	1
Ruocco, HH	2
Lopes-Cendes, I	2
Cendes, F	2
Castellano, G	1
Gil-Mohapel, J	1
Brocardo, PS	1
Christie, BR	1
McCusker, EA	1
Myers, RH	1
Doros, G	1
Gevorkian, S	2
Malarick, K	1
Reuter, M	1
Coutu, JP	1
Triggs, TD	1
Wilkens, PJ	1
Matson, W	2
Salat, DH	1
Tuckfield, C	1
Shannon, KM	1
Fraint, A	1
Oláh, J	1
Klivényi, P	1
Gardián, G	1
Vécsei, L	1
Orosz, F	1
Kovacs, GG	1
Westerhoff, HV	1
Ovádi, J	1
Reynolds, NC	1
Prost, RW	1
Mark, LP	1
Joseph, SA	1
Yang, L	3
Calingasan, NY	1
Wille, EJ	1
Cormier, K	1
Smith, K	1
Ferrante, RJ	5
Beal, MF	6
Lin, YS	3
Chen, CM	1
Soong, BW	1
Wu, YR	1
Chen, HM	1
Yeh, WY	1
Wu, DR	1
Lin, YJ	1
Poon, PW	1
Cheng, ML	1
Wang, CH	2
Chern, Y	3
Naia, L	1
Ribeiro, MJ	1
Rego, AC	1
Ju, TC	1
Dedeoglu, A	2
Kubilus, JK	2
Ferrante, KL	1
Tabrizi, SJ	2
Blamire, AM	2
Manners, DN	2
Rajagopalan, B	2
Styles, P	3
Schapira, AH	2
Warner, TT	2
Bates, GP	2
Hockly, E	2
Baker, SK	1
Tarnopolsky, MA	1
Verbessem, P	1
Lemiere, J	1
Eijnde, BO	1
Swinnen, S	1
Vanhees, L	1
Van Leemputte, M	1
Hespel, P	1
Dom, R	1
Couzin, J	1
Bender, A	1
Auer, DP	1
Merl, T	1
Reilmann, R	1
Saemann, P	1
Yassouridis, A	1
Bender, J	1
Weindl, A	1
Dose, M	1
Gasser, T	1
Klopstock, T	1
Ryu, H	1
Marder, K	1
Moskowitz, C	1
Feigin, A	1
Cox, M	1
Como, P	1
Zimmerman, C	1
Lin, M	1
Zhang, L	1
Ulug, AM	1
Bogdanov, M	1
Ebbel, E	1
Zaleta, A	1
Kaneko, Y	1
Jenkins, B	1
Hevelone, N	1
Zhang, H	1
Yu, H	1
Schoenfeld, D	1
Ferrante, R	1
Martin, WR	1
Wieler, M	1
Hanstock, CC	1
Li, LM	1
van Oostrom, JC	1
Sijens, PE	1
Roos, RA	1
Leenders, KL	1
Taylor-Robinson, SD	1
Weeks, RA	1
Sargentoni, J	1
Marcus, CD	1
Bryant, DJ	1
Harding, AE	1
Brooks, DJ	1
Jenkins, BG	3
Koroshetz, WJ	1
Rosen, BR	2
Matthews, RT	1
Kaddurah-Daouk, R	2
Andreassen, OA	1
Kuemmerle, S	1
van Dellen, A	1
Welch, J	1
Dixon, RM	1
Cordery, P	1
York, D	1
Blakemore, C	1
Hannan, AJ	1
Smith, DL	1
Portier, R	1
Woodman, B	1
Mahal, A	1
Klunk, WE	1
Li, XJ	1
Wanker, E	1
Murray, KD	1
Menalled, LB	1
Chesselet, MF	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)[NCT00712426]	Phase 3	553 participants (Actual)	Interventional	2009-09-30	Terminated (stopped due to Results of an interim analysis showed that it was unlikely that creatine was effective in slowing loss of function in early symptomatic Huntington's Disease.)
Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881]	Phase 3	609 participants (Actual)	Interventional	2008-03-31	Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.)
Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study[NCT01411150]	Phase 2	38 participants (Actual)	Interventional	2009-05-31	Completed
Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability[NCT01411163]	Phase 2	24 participants (Actual)	Interventional	2010-04-30	Completed
Creatine Safety and Tolerability in Premanifest HD: PRECREST[NCT00592995]	Phase 2	64 participants (Actual)	Interventional	2007-12-31	Completed
Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HD[NCT01412151]	Phase 2	10 participants (Actual)	Interventional	2005-04-30	Completed
An Investigation Examining the Evidence for Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder[NCT00327756]	Phase 2	0 participants (Actual)	Interventional	2006-05-31	Withdrawn
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Behavioral Frequency x Severity Score From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	1.39
B - Placebo	1.43

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Functional Checklist Score From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	4.29
B - Placebo	5.06

"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60

Change in Independence Scale Score From Baseline to Month 60

Intervention	units on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day	-7.93
B - Placebo	-8.02

The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Stroop Interference Test - Color Naming From Baseline to Month 60

Intervention	units on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day	-26.30
B - Placebo	-24.86

Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Stroop Interference Test - Interference From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	-14.21
B - Placebo	-14.51

Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Stroop Interference Test - Word Reading From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	-7.57
B - Placebo	-8.61

Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	-15.25
B - Placebo	-19.13

The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Total Functional Capacity (TFC) Score From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	-10.95
B - Placebo	-11.36

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60

Change in Total Motor Score From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	-4.53
B - Placebo	-4.76

The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Verbal Fluency Test From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	18.06
B - Placebo	19.18

The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60

Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	-5.07
B - Placebo	-4.47

The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Number Completing Study at Assigned Dosage Level

Time to a Three-Point Decline in TFC Score or Death

Intervention	rank (Mean)
A - Coenzyme Q10 2400 mg/Day	303.3
B - Placebo	306.7

Intervention	participants completing study on drug (Number)
A - Coenzyme Q10 2400 mg/Day	98
B - Placebo	108

Time to a Two-Point Decline in TFC Score or Death

Intervention	days to event (Median)
A - Coenzyme Q10 2400 mg/Day	917
B - Placebo	911

Tolerability

Intervention	days to event (Median)
A - Coenzyme Q10 2400 mg/Day	553
B - Placebo	549

Proportion of subjects able to complete treatment (NCT01412151)
Timeframe: 306 Weeks

Reviews

9 reviews available for creatine and Akinetic-Rigid Variant of Huntington Disease

Trials

7 trials available for creatine and Akinetic-Rigid Variant of Huntington Disease

Other Studies

19 other studies available for creatine and Akinetic-Rigid Variant of Huntington Disease

Article	Year
The role of oxidative stress in Huntington's disease: are antioxidants good therapeutic candidates? Current drug targets, 2014, Volume: 15, Issue:4 Topics: Animals; Antioxidants; Cell Death; Clinical Trials as Topic; Creatine; Fatty Acids, Essential; Human	2014
Therapeutic advances in Huntington's Disease. Movement disorders : official journal of the Movement Disorder Society, 2015, Sep-15, Volume: 30, Issue:11 Topics: Clinical Trials as Topic; Creatine; Humans; Huntington Disease; Ubiquinone; Vitamins	2015
Besides Huntington's disease, does brain-type creatine kinase play a role in other forms of hearing impairment resulting from a common pathological cause? Aging, 2011, Volume: 3, Issue:6 Topics: Animals; Cochlea; Creatine; Creatine Kinase, BB Form; Hearing Loss; Humans; Huntington Disease; Mice	2011
Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q. Reviews in the neurosciences, 2011, Dec-02, Volume: 23, Issue:1 Topics: Animals; Creatine; Disease Models, Animal; Humans; Huntington Disease; Metabolic Diseases; Mitochond	2011
Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB. Cellular and molecular life sciences : CMLS, 2012, Volume: 69, Issue:24 Topics: AMP-Activated Protein Kinases; Animals; Creatine; Creatine Kinase, BB Form; Energy Metabolism; Heat-	2012
Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? Current opinion in neurology, 2003, Volume: 16, Issue:4 Topics: Acetamides; Animals; Antioxidants; Creatine; Disease Models, Animal; Evaluation Studies as Topic; Hu	2003
Targeting cellular energy production in neurological disorders. Expert opinion on investigational drugs, 2003, Volume: 12, Issue:10 Topics: Amyotrophic Lateral Sclerosis; Animals; Coenzymes; Creatine; Disease Models, Animal; Energy Metaboli	2003
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
The therapeutic role of creatine in Huntington's disease. Pharmacology & therapeutics, 2005, Volume: 108, Issue:2 Topics: Animals; Creatine; Humans; Huntington Disease; Nervous System Diseases	2005
Mouse models of Huntington's disease. Trends in pharmacological sciences, 2002, Volume: 23, Issue:1 Topics: Animals; Creatine; Dichloroacetic Acid; Enzyme Inhibitors; Humans; Huntingtin Protein; Huntington Di	2002

Article	Year
The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology, 2017, Aug-08, Volume: 89, Issue:6 Topics: Australia; Creatine; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Hu	2017
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology, 2014, Mar-11, Volume: 82, Issue:10 Topics: Adult; Atrophy; Biomarkers; Brain; Cognition Disorders; Creatine; Cross-Over Studies; Diffusion Magn	2014
Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology, 2003, Jul-08, Volume: 61, Issue:1 Topics: Adenosine Triphosphate; Aspartic Acid; Brain; Choline; Creatine; Diarrhea; Dietary Supplements; Dose	2003
Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology, 2003, Oct-14, Volume: 61, Issue:7 Topics: Cognition; Creatine; Dietary Supplements; Double-Blind Method; Female; Humans; Huntington Disease; M	2003
Creatine supplementation lowers brain glutamate levels in Huntington's disease. Journal of neurology, 2005, Volume: 252, Issue:1 Topics: Administration, Oral; Adult; Aspartic Acid; Brain; Cerebral Cortex; Creatine; Down-Regulation; Energ	2005
High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology, 2005, May-10, Volume: 64, Issue:9 Topics: Administration, Oral; Aspartic Acid; Body Weight; Brain; Creatine; Creatinine; Dose-Response Relatio	2005
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Biological Availability; Biomarkers; Brain; Creatine; Deoxyguano	2006

Article	Year
Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington's disease for participants of varying functional disability: a pilot study. Scientific reports, 2020, 11-24, Volume: 10, Issue:1 Topics: Adult; Arginine; Biomarkers; Creatine; Cross-Sectional Studies; Disability Evaluation; Female; Glyci	2020
Thalamic metabolic abnormalities in patients with Huntington's disease measured by magnetic resonance spectroscopy. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2013, Volume: 46, Issue:8 Topics: Adolescent; Adult; Aged; Aspartic Acid; Case-Control Studies; Creatine; Deuterium; Dipeptides; Femal	2013
Feasibility of Huntington disease trials in the disease prodrome. Neurology, 2014, Mar-11, Volume: 82, Issue:10 Topics: Brain; Cognition Disorders; Creatine; Humans; Huntington Disease	2014
First use of creatine hydrochloride in premanifest Huntington disease. The Medical journal of Australia, 2015, Apr-20, Volume: 202, Issue:7 Topics: Adult; Central Nervous System Agents; Creatine; Female; Humans; Huntington Disease	2015
Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice. The FEBS journal, 2008, Volume: 275, Issue:19 Topics: Adenosine Triphosphate; Animals; Brain; Creatine; Female; Glucose; Glyceraldehyde-3-Phosphate Dehydr	2008
MR-spectroscopic findings in juvenile-onset Huntington's disease. Movement disorders : official journal of the Movement Disorder Society, 2008, Oct-15, Volume: 23, Issue:13 Topics: Adolescent; Aspartic Acid; Brain Mapping; Child; Child, Preschool; Creatine; Female; Glutamic Acid;	2008
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. Journal of neurochemistry, 2009, Volume: 109, Issue:5 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2'-Deoxyguanosine; alpha-Synuclein; Analysis	2009
Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. The Journal of clinical investigation, 2011, Volume: 121, Issue:4 Topics: Adult; Animals; Audiometry, Pure-Tone; Blotting, Western; Case-Control Studies; Cochlea; Creatine; C	2011
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Huntington's disease. Unorthodox clinical trials meld science and care. Science (New York, N.Y.), 2004, May-07, Volume: 304, Issue:5672 Topics: Animals; Blueberry Plants; Clinical Trials as Topic; Creatine; Cysteamine; Drug Therapy, Combination	2004
Is brain lactate increased in Huntington's disease? Journal of the neurological sciences, 2007, Dec-15, Volume: 263, Issue:1-2 Topics: Adult; Aspartic Acid; Brain; Case-Control Studies; Choline; Creatine; Female; Humans; Huntington Dis	2007
Evidence of thalamic dysfunction in Huntington disease by proton magnetic resonance spectroscopy. Movement disorders : official journal of the Movement Disorder Society, 2007, Oct-31, Volume: 22, Issue:14 Topics: Adult; Age of Onset; Aged; Analysis of Variance; Aspartic Acid; Creatine; Female; Humans; Huntington	2007
1H magnetic resonance spectroscopy in preclinical Huntington disease. Brain research, 2007, Sep-07, Volume: 1168 Topics: Adult; Age Factors; Analysis of Variance; Aspartic Acid; Brain; Brain Mapping; Choline; Creatine; Fe	2007
Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy. Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906 Topics: Corpus Striatum; Creatine; Glutamine; Humans; Huntington Disease; Magnetic Resonance Spectroscopy	1994
Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology, 1993, Volume: 43, Issue:12 Topics: Adult; Aspartic Acid; Basal Ganglia; Choline; Creatine; Energy Metabolism; Female; Humans; Huntingto	1993
Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 1998, Jan-01, Volume: 18, Issue:1 Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Antineoplastic Agents; Creatine; Creatinin	1998
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12 Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr	2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12 Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr	2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12 Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr	2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12 Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr	2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12 Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr	2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12 Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr	2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12 Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr	2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12 Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr	2000
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Jun-15, Volume: 20, Issue:12 Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr	2000
N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport, 2000, Nov-27, Volume: 11, Issue:17 Topics: Animals; Aspartic Acid; Biomarkers; Calbindins; Choline; Corpus Striatum; Creatine; Dopamine and cAM	2000
Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiology of disease, 2001, Volume: 8, Issue:6 Topics: Animals; Benzoates; Biphenyl Compounds; Cells, Cultured; Coloring Agents; Congo Red; Creatine; Cyste	2001